Another development in one of Europe’s most modern injection production plants - VIDEO REPORT
2020. 09. 17.
Following the investments of the past years, Sanofi is now launching another significant expansion project in its Csanyikvölgy plant near Miskolc. As a result of this over EUR 22 million expansion production capacity for pre-filled syringes will be increased by 50 percent, remarkably improving the patients' access to the French giant's life-saving, anticoagulant medicinal product.
Sanofi, founded in 1973, is one of the leading pharmaceutical stakeholders worldwide, and its products are distributed in 170 countries. The company group with headquarters in Paris employs over 100,000 people in 100 countries and pays special attention to research and development.
As the second largest healthcare company in Hungary and the 15th most important exporter for the country, Sanofi has been a strategic partner to the Hungarian government since 2013. The company has five sites in Hungary. Chemical development and production take place at the central premises and R&D centre in Budapest, but Sanofi also has production units in Veresegyháza and Csanyikvölgy near Miskolc. Additionally, the logistics and distribution centre in Nagytétény supplies more than 50 customers with the products of 59 factories through the provision of some 290 million packages of medicine on a yearly basis.
The healthcare products manufactured in Csanyikvölgy require a high level of production safety, sterilized conditions and an exceptionally high level of expertise. Terminally sterilized ampoules, injections and aseptically produced, pre-filled syringes are manufactured with the use of world-class technology. The production unit provides employment for over 400 highly-skilled experts, making it one of the biggest employers in Northeastern Hungary.
Over recent years, investments in excess of HUF 24 billion have been accomplished at the Csanyikvölgy production unit, making the manufacturing site one of the most cutting-edge injection plants in Europe. The anticoagulants manufactured on the new high-speed production line of pre-filled sterilized syringes will enter the markets as from April 2022.
